Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AstraZeneca and Targacept have initiated a Phase 2b clinical trial of TC-5214, a nicotinic channel blocker, as a ‘switch’ monotherapy treatment for patients with major depressive disorder (MDD) who do not respond adequately to initial antidepressant therapy.
Subscribe to our email newsletter
The study is in addition to the companies’ joint Phase 3 RENAISSANCE Program for TC-5214 as an adjunctive treatment for MDD.
The RENAISSANCE Program is designed to support a new drug application filing planned for the second half of 2012 and a marketing authorization application filing in Europe planned for 2015.
The primary outcome measure for the study is change from double-blind baseline at the end of the dosing period for TC-5214 on the Montgomery-Asberg Depression Rating Scale (MADRS) as compared to placebo.